Related Experiment Video

Updated: Jul 19, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer

Eric Van Cutsem1

  • 1Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven, Belgium. Eric.VanCutsem@uz.kuleuven.ac.be

The Oncologist
|October 13, 2006
PubMed

Insights

New targeted therapies, including monoclonal antibodies against the epidermal growth factor receptor (EGFR), offer new options for metastatic colorectal cancer (mCRC). Optimal integration with chemotherapy and toxicity management remain key challenges.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Metastatic colorectal cancer (mCRC) treatment is evolving with novel targeted agents.
  • Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) show activity in irinotecan-refractory mCRC and earlier stages of colorectal cancer (CRC).

Purpose of the Study:

  • To review the efficacy and challenges of using EGFR monoclonal antibodies in mCRC treatment.
  • To discuss the integration of EGFR inhibitors with chemotherapy and toxicity management.

Main Methods:

  • Review of existing clinical trial data and literature on EGFR monoclonal antibodies in mCRC.
  • Analysis of combination strategies with chemotherapy and patient selection criteria.

Main Results:

  • Cetuximab and panitumumab are active EGFR monoclonal antibodies in mCRC.
  • Combination of EGFR antibodies with irinotecan or standard chemotherapy regimens shows promising activity.
  • Rash occurrence correlates with response, but baseline EGFR expression does not predict efficacy.

Conclusions:

  • EGFR monoclonal antibodies represent a significant advancement in mCRC therapy.
  • Further research is needed to establish optimal scheduling, integration with chemotherapy, and patient selection strategies.
  • Management of treatment-related toxicities, such as rash, is crucial for successful therapy.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...